NBIX Neurocrine Biosciences, Inc. - Common Stock

NASDAQ · Biotechnology · SEC EDGAR에서 보기 ↗
$155.47
가격 · 8월 19, 2026
기준 재무 정보 7월 31, 2026
52주 범위
$123–$186
51% of range
애널리스트 평점
BUY
36 analysts
목표 주가
$212
+36% upside
P/E (TTM)
33.3
ROE
16.1%
순이익률
16.7%

Neurocrine Biosciences, Inc. - Common Stock 정보 위키백과 회사 개요

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

더 보기

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

History

Neurocrine was founded in San Diego, California, in 1992. The company's academic founders were Wylie Vale of the Salk Institute for Biological Studies, and Lawrence Steinman of Stanford University. The company was backed and organized by Larry Bock of Avalon Ventures among others.

In 1995, the company collaborated with Belgium-based Janssen Pharmaceutica N.V. to develop treatments for psychiatric disorders utilizing corticotropin releasing factor (CRF) antagonists, a class of compounds to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression and irritable bowel syndrome. The company underwent an IPO in May 1996, listing on the NASDAQ exchange under the symbol NBIX and raising $34.2 million.

In October 1996, Eli Lilly and Company agreed to pay Neurocrine $74 million over five years to develop drugs for obesity and Alzheimer's disease based on its research of CRF-binding protein-ligand inhibitors.

In July 2001, Neurocrine and GlaxoSmithKline entered into a worldwide research, development and commercialization agreement, including a collaborative research program for up to five years to identify and develop CRF-R antagonist compounds. The collaboration also included worldwide development and commercialization of NBI-34041 as well as potential backup candidates resulting from the research program. Neurocrine received upfront fees and early milestone payments totaling $25.5 million.

In December 2002, Neurocrine reached an agreement with Pfizer for the rights to its experimental insomnia drug, indiplon. The deal paid Neurocrine $100 million initially with a possible $300 million more if the drug met regulatory and sales goals. In May 2006, the FDA issued a non-approvable letter for a modified-release 15 mg formulation of indiplon and an approvable letter with stipulations for 5 mg and 10 mg immediate-release formulations. As a result, Pfizer terminated its agreement with Neurocrine. Following a resubmission of the 5 mg and 10 mg formulations in December 2007, Neurocrine's new drug application was deemed 'approvable' but the FDA requested additional studies. The company discontinued development of the drug in the United States. In 2007, Neurocrine partnered with Dainippon Sumitomo Pharma to develop and commercialize indiplon in Japan. The deal paid Neurocrine $20 million up front with the ability to receive milestone payments and royalties based on the commercialization of indiplon in Japan.

Kevin Gorman replaced Gary Lyons as CEO of the company in January 2008. Lyons was CEO and president of the company since its founding and maintained a role on the company's board of directors.

On June 16, 2010, Neurocrine agreed to a deal with AbbVie Inc. (previously Abbott Laboratories) worth up to $575 million with Neurocrine granting AbbVie the worldwide rights to develop and commercialize elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist to treat endometriosis and uterine fibroids. The deal paid Neurocrine $75 million up front.

In April 2017, the FDA approved valbenazine for the treatment of TD. At the time of approval, it was the first and only drug approved for adults with TD. Neurocrine is also studying valbenazine in clinical trials for the treatment of Tourette Syndrome. In October 2017, Neurocrine announced that it had been granted orphan drug designation status from the FDA for valbenazine for the treatment of pediatric patients with Tourette syndrome.

In February 2017, Neurocrine announced an exclusive licensing agreement for the development and commercialization of the Parkinson's disease drug, opicapone, in North America with the Portugal-based pharmaceutical company Bial. As part of the agreement, Neurocrine provided an upfront payment of $30 million and agreed to fund development activities for FDA approval in the United States. Bial is eligible to receive additional milestone payments of up to $115 million and a percentage of net sales.

In September 2017, AbbVie submitted a NDA to the FDA for elagolix for the management of endometriosis and associated pain. The submission was supported by two similar Phase 3 clinical studies involving 1,700 women. In October 2017, AbbVie and Neurocrine announced that the FDA granted priority review for the elagolix NDA. A final regulatory decision on the drug will come during the third quarter of 2018. The companies are also developing elagolix for the treatment of uterine fibroids which is in Phase III development.

In 2021,Nexera Pharmain Japan licensed out its investigational schizophrenia drug, NBI-1117568, to Neurocrine Biosciences for development.

In August 2024, Neurocrine announced the results of a Phase II clinical trial of NBI-1117568 . The drug demonstrated a 7.5-point improvement in the Positive and Negative Syndrome Scale (PANSS), which was lower than the 8.4-point improvement seen with KarXT (developed by Karuna Therapeutics) and the 12.7-point improvement seen with Emraclidine (developed by Cerevel Therapeutics), both of which were also in clinical trials at the time. Additionally, the study found no dose-dependent response to NBI-1117568. As a result, Neurocrine's stock price fell 19% the following day as investors were disappointed by the results.

Product pipeline

Elagolix – gonadotropin-releasing hormone receptor antagonist undergoing FDA review for the treatment of endometriosis and in clinical trials for uterine fibroids

Opicapone – A once daily catechol-O-methyl transferase inhibitor in trials for Parkinson's disease

NBI-74788 – Corticotropin-releasing factor (CRF) receptor antagonist

NBI-1117568 - A drug that stimulates muscarinic receptors and is used to treat schizophrenia.

출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗

Wikidata ↗

NBIX 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위

가격
$155.47
시가총액
$15.56B
P/E (TTM)
33.3
EPS (TTM)
$4.67
매출 (TTM)
$2.86B
배당 수익률
—
ROE
16.1%
부채/자본
—
52주 범위
$123 – $186

NBIX 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의

10년 성과 매출, 순이익, 마진 및 EPS 추세

매출 및 순이익 $2.86B
10-point trend, +18970.0%
2016-12-31 → 2025-12-31
EPS $4.67
10-point trend, +386.5%
2016-12-31 → 2025-12-31
잉여현금흐름 $749M
10-point trend, +778.9%
2016-12-31 → 2025-12-31
마진 16.7%

가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?

지표
5년 추세
NBIX
동종업계 중앙값
P/E (TTM)
5-point trend, -67.2%
33.3
16.9
P/S (TTM)
5-point trend, -30.4%
5.4
9.6
P/B
5-point trend, -25.8%
4.8
7.7
Price / FCF (주가 / FCF)
5-point trend, -45.3%
20.8
—

수익성 총, 영업 및 순이익률; ROE, ROA, ROIC

지표
5년 추세
NBIX
동종업계 중앙값
Operating Margin (영업이익률)
5-point trend, +139.4%
21.6%
—
Net Profit Margin (순이익률)
5-point trend, +111.8%
16.7%
-36.9%
ROA
5-point trend, +143.3%
11.5%
-21.8%
ROE
5-point trend, +144.2%
16.1%
-47.3%
ROIC
5-point trend, +95.9%
12.9%
—

재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성

지표
5년 추세
NBIX
동종업계 중앙값
Current Ratio (유동비율)
5-point trend, -14.3%
3.4
3.5
Quick Ratio (당좌 비율)
5-point trend, -48.4%
1.9
—

성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR

지표
5년 추세
NBIX
동종업계 중앙값
Revenue YoY (매출 YoY)
5-point trend, +152.4%
21.4%
—
Revenue CAGR 3Y (매출 CAGR 3년)
5-point trend, +152.4%
24.3%
—
Revenue CAGR 5Y (매출 CAGR 5년)
5-point trend, +152.4%
22.3%
—
EPS YoY
5-point trend, +407.6%
41.9%
—
Net Income YoY (순이익 YoY)
5-point trend, +434.2%
40.2%
—

주당 지표 EPS, 주당 순자산, 주당 현금 흐름, 주당 배당금

지표
5년 추세
NBIX
동종업계 중앙값
EPS (Diluted) (EPS (희석))
5-point trend, +407.6%
$4.67
—

자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율

지표
5년 추세
NBIX
동종업계 중앙값

NBIX 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력

매수 36 명의 애널리스트
  • 적극 매수 14 38.9%
  • 매수 17 47.2%
  • 보유 5 13.9%
  • 매도 0 0.0%
  • 적극 매도 0 0.0%

12개월 목표 주가

27 명의 애널리스트 · 2026-08-15
중앙값 목표 $215.00 +38.3%
평균 목표 $211.57 +36.1%

실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일

평균 서프라이즈
0.24%
기간 EPS Actual EPS 예상 서프라이즈
2026년 6월 30일 $1.39 $1.37 0.02%
2026년 3월 31일 $1.91 $1.20 0.71%
2025년 12월 31일 $1.91 $1.20 0.71%
2025년 9월 30일 $2.04 $1.62 0.42%
2025년 6월 30일 $1.06 $0.99 0.07%
2025년 3월 31일 $0.08 $0.56 -0.48%

동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업

티커 시가총액 P/E 매출 YoY 순이익률 ROE 매출 총이익률
NBIX $14.20B 30.4 21.4% 16.7% 16.1% —
INCY $19.60B 15.4 21.2% 25.0% 27.6% —
MRNA $11.62B -4.1 -39.9% -145.2% -31.3% —
UTHR $21.27B 17.5 10.6% 41.9% 18.7% 87.9%
BBIO $14.90B -20.2 126.3% -146.0% 41.2% —
BMRN $11.43B 33.0 12.9% 10.8% 5.8% —
EXEL $11.44B 15.7 7.0% 33.7% 37.3% —
ARWR $4.68B -3449.0 23258.2% -0.20% -0.50% —
MDGL $13.30B -45.3 432.1% -30.1% -44.4% —
HALO $7.93B 26.3 37.5% 22.7% 166.1% —

전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름

손익계산서 17
NBIX의 연간 손익계산서 데이터
지표 추세 202520242023202220212020201920182017201620152014
Revenue 12-point trend, +2860500000.00 $2.86B $2.36B $1.89B $1.49B $1.13B $1.05B $788M $451M $162M $15M $20M $0
Cost of Revenue 10-point trend, +52100000.00 $52M $34M $40M $23M $14M $10M · $5M $1M $0 $0 ·
R&D Expense 5-point trend, +245.8% · · · · · · · $161M $122M $94M $81M $46M
SG&A Expense 12-point trend, +6328.3% $1.16B $1.01B $888M $753M $583M $433M $354M $249M $170M $68M $32M $18M
Operating Expenses 12-point trend, +3379.8% $2.24B $1.78B $1.64B $1.24B $1.03B $883M $716M $414M $293M $162M $114M $64M
Operating Income 12-point trend, +1061.2% $619M $570M $251M $249M $102M $163M $72M $37M $-131M $-147M $-94M $-64M
Interest Expense 9-point trend, +4600000.00 · · $5M $7M $26M $33M $32M $30M $20M $0 $0 ·
Interest Income 3-point trend, +351.2% · · · · · · · · · $3M $2M $629.0K
Other Non-op 12-point trend, +479344.4% $86M $-84M $81M $-35M $-1M $-56M $-26M $-15M $-11M $6M $20.0K $18.0K
Pretax Income 10-point trend, +600.0% $705M $486M $332M $214M $101M $107M $46M $22M $-143M $-141M · ·
Income Tax 12-point trend, +226800000.00 $227M $145M $82M $59M $12M $-301M $10M $700.0K $0 $0 $0 $0
Net Income 12-point trend, +890.5% $479M $341M $250M $154M $90M $407M $37M $21M $-143M $-141M $-89M $-61M
EPS (Basic) 12-point trend, +693.8% $4.81 $3.40 $2.56 $1.61 $0.95 $4.38 $0.40 $0.23 $-1.62 $-1.63 $-1.05 $-0.81
EPS (Diluted) 12-point trend, +676.5% $4.67 $3.29 $2.47 $1.56 $0.92 $4.16 $0.39 $0.22 $-1.62 $-1.63 $-1.05 $-0.81
Shares (Basic) 12-point trend, +33.4% 99,500,000 100,400,000 97,700,000 95,800,000 94,600,000 93,100,000 91,600,000 90,200,000 88,089,000 86,713,000 84,496,000 74,577,000
Shares (Diluted) 12-point trend, +37.4% 102,500,000 103,700,000 101,000,000 98,900,000 97,900,000 97,800,000 95,700,000 95,400,000 88,089,000 86,713,000 84,496,000 74,577,000
EBITDA 11-point trend, +1061.2% $619M $570M $251M $249M $102M $163M $72M $37M $-131M $-147M · $-64M
대차대조표 28
NBIX의 연간 대차대조표 데이터
지표 추세 202520242023202220212020201920182017201620152014
Cash & Equivalents 12-point trend, +2199.0% $713M $233M $251M $263M $341M $187M $112M $142M $255M $83M $74M $31M
Short-term Investments 8-point trend, +127.6% · · · · $370M $614M $558M $509M $261M $224M $305M $163M
Receivables 10-point trend, +686800000.00 $687M $479M $439M $350M $186M $157M $127M $57M $31M $0 · ·
Inventory 10-point trend, +69000000.00 $69M $57M $38M $35M $30M $28M $17M $11M $1M $0 · ·
Prepaid Expense 2-point trend, +252.0% $171M $48M · · · · · · · · · ·
Other Current Assets 12-point trend, +2535.4% $116M $64M $98M $79M $46M $30M $17M $19M $7M $3M $5M $4M
Current Assets 12-point trend, +1172.8% $2.52B $1.72B $1.61B $1.45B $973M $1.02B $831M $738M $555M $310M $384M $198M
PP&E (Net) 12-point trend, +3482.0% $90M $83M $71M $59M $59M $45M $42M $34M $11M $6M $3M $3M
PP&E (Gross) 12-point trend, +565.9% $208M $189M $154M $125M $110M $86M $76M $62M $38M $32M $30M $31M
Accum. Depreciation 12-point trend, +311.5% $118M $106M $83M $66M $52M $42M $34M $28M $28M $26M $27M $29M
Goodwill 5-point trend, +6100000.00 $6M $6M $6M $5M $0 · · · · · · ·
Intangibles 5-point trend, +4700000.00 $5M $36M $36M $37M $0 · · · · · · ·
Other Non-current Assets 7-point trend, +48700000.00 $49M $52M $50M $25M $4M $6M $0 · · · · ·
Total Assets 12-point trend, +1805.7% $4.63B $3.72B $3.25B $2.37B $2.07B $1.73B $1.31B $993M $818M $365M $475M $243M
Accounts Payable 12-point trend, +274005.7% $674M $462M $449M $348M $226M $169M $141M $86M $6M $5M $3M $246.0K
Accrued Liabilities 3-point trend, +83.3% · · · · · · · · · $21M $19M $12M
Current Liabilities 12-point trend, +4645.9% $743M $508M $655M $538M $246M $186M $565M $88M $54M $30M $26M $16M
Capital Leases 8-point trend, +415300000.00 $415M $455M $258M $94M $105M $94M $87M $0 · · · ·
Deferred Tax $0 · · · · · · · · · · ·
Other Non-current Liabilities 12-point trend, +84400.0% $220M $166M $106M $30M $12M $10M $17M $36M $0 $113.0K $221.0K $260.0K
Total Liabilities 12-point trend, +3914.7% $1.38B $1.13B $1.02B $661M $698M $608M $669M $512M $445M $50M $50M $34M
Common Stock 12-point trend, +31.6% $100.0K $100.0K $100.0K $100.0K $100.0K $100.0K $100.0K $91.0K $89.0K $87.0K $86.0K $76.0K
Paid-in Capital · · · · · · · · · · · $1.04B
Retained Earnings 12-point trend, +154.2% $448M $29M $-157M $-407M $-636M $-725M $-1.13B $-1.18B $-1.20B $-1.06B $-915M $-826M
AOCI 12-point trend, +4829.2% $13M $6M $7M $-8M $-2M $2M $1M $-2M $-2M $-318.0K $-977.0K $-277.0K
Stockholders' Equity 12-point trend, +1458.8% $3.25B $2.59B $2.23B $1.71B $1.37B $1.13B $637M $481M $372M $315M $424M $209M
Liabilities + Equity 12-point trend, +1805.7% $4.63B $3.72B $3.25B $2.37B $2.07B $1.73B $1.31B $993M $818M $365M $475M $243M
Shares Outstanding 12-point trend, +30.9% 100,100,000 99,400,000 98,700,000 96,500,000 94,900,000 93,500,000 92,300,000 90,797,000 88,793,903 86,883,300 86,262,594 76,465,942
현금 흐름 15
NBIX의 연간 현금 흐름 데이터
지표 추세 202520242023202220212020201920182017201620152014
D&A 5-point trend, +386.6% · · · · · · · $4M $2M $1M $1M $827.0K
Stock-based Comp 12-point trend, +1998.8% $218M $196M $194M $173M $134M $100M $75M $58M $43M $28M $28M $10M
Deferred Tax 8-point trend, +164200000.00 $164M $-123M $-61M $22M $6M $-311M $0 $0 · · · ·
Amort. of Intangibles 6-point trend, +4100000.00 $4M $4M $4M $500.0K $0 $0 · · · · · ·
Operating Cash Flow 12-point trend, +1760.4% $783M $595M $390M $339M $256M $228M $147M $101M $-94M $-106M $-38M $-47M
CapEx 12-point trend, +2009.2% $34M $38M $28M $16M $23M $11M $15M $25M $7M $4M $2M $2M
Investing Cash Flow 10-point trend, -334.1% $-264M $-127M $-467M $-177M $-130M $4M $-211M $-243M $-251M $113M · ·
Stock Issued 12-point trend, -6.7% $129M $122M $65M $45M $28M $29M $32M $30M $14M $2M $277M $139M
Stock Repurchased 4-point trend, +167700000.00 $168M $300M $0 $0 · · · · · · · ·
Net Stock Activity 11-point trend, -127.6% $-38M $-178M $65M $45M $28M $29M $27M $30M $14M $2M · $139M
Financing Cash Flow 10-point trend, -1702.5% $-38M $-487M $65M $-234M $27M $-158M $32M $30M $517M $2M · ·
Net Change in Cash 12-point trend, +3584.6% $480M $-18M $-12M $-73M $154M $75M $-32M $-112M $171M $9M $43M $-14M
Taxes Paid $81M · · · · · · · · · · ·
Free Cash Flow 11-point trend, +1635.7% $749M $557M $362M $323M $233M $218M $137M $77M $-101M $-110M · $-49M
Levered FCF 6-point trend, +661.3% · · $358M $318M $210M $92M $112M $47M · · · ·
수익성 7
NBIX의 연간 수익성 데이터
지표 추세 202520242023202220212020201920182017201620152014
Operating Margin 10-point trend, +102.2% 21.6% 24.2% 13.3% 16.7% 9.0% 15.6% 9.2% 8.2% -81.3% -982.5% · ·
Net Margin 10-point trend, +101.8% 16.7% 14.5% 13.2% 10.4% 7.9% 38.9% 4.7% 4.7% -88.2% -940.6% · ·
Pretax Margin 8-point trend, +409.5% 24.7% 20.6% 17.6% 14.4% 8.9% 10.2% 5.9% 4.8% · · · ·
EBITDA Margin 10-point trend, +102.2% 21.6% 24.2% 13.3% 16.7% 9.0% 15.6% 9.2% 8.2% -81.3% -982.5% · ·
ROA 11-point trend, +137.6% 11.5% 9.8% 8.9% 7.0% 4.7% 26.8% 3.2% 2.3% -24.1% -33.6% · -30.4%
ROE 11-point trend, +143.7% 16.1% 12.9% 11.8% 9.5% 6.6% 42.2% 6.1% 4.5% -41.5% -38.2% · -36.8%
ROIC 8-point trend, +74.0% 12.9% 15.5% 8.5% 10.5% 6.6% 55.2% 9.0% 7.4% · · · ·
유동성 및 지급능력 3
NBIX의 연간 유동성 및 지급능력 데이터
지표 추세 202520242023202220212020201920182017201620152014
Current Ratio 11-point trend, -73.2% 3.4 3.4 2.5 2.7 4.0 5.4 1.5 8.4 10.2 10.2 · 12.7
Quick Ratio 11-point trend, -84.8% 1.9 1.4 1.1 1.1 3.6 5.1 1.4 2.2 10.1 10.1 · 12.4
Interest Coverage 7-point trend, +910.6% · · 54.5 35.1 4.0 5.0 2.3 1.2 -6.7 · · ·
효율성 3
NBIX의 연간 효율성 데이터
지표 추세 202520242023202220212020201920182017201620152014
Asset Turnover 11-point trend, +0.69 0.7 0.7 0.7 0.7 0.6 0.7 0.7 0.5 0.3 0.0 · 0.0
Inventory Turnover 5-point trend, +0.2% 0.8 0.7 1.1 0.7 · · · 0.8 · · · ·
Receivables Turnover 9-point trend, -52.7% 4.9 5.1 4.8 5.6 6.6 7.4 8.6 10.3 10.4 · · ·
주당 5
NBIX의 연간 주당 데이터
지표 추세 202520242023202220212020201920182017201620152014
Book Value / Share 11-point trend, +1090.7% $32.50 $26.05 $22.61 $17.70 $14.48 $12.04 $6.90 $5.29 $4.19 $3.62 · $2.73
Revenue / Share 11-point trend, +27.91 $27.91 $22.71 $18.68 $15.05 $11.58 $10.69 $8.23 $4.73 $1.83 $0.17 · $0.00
Cash Flow / Share 11-point trend, +1308.1% $7.64 $5.74 $3.86 $3.43 $2.62 $2.34 $1.59 $1.06 $-1.07 $-1.22 · $-0.63
Cash / Share 11-point trend, +1656.1% $7.12 $2.34 $2.54 $2.72 $3.59 $2.00 $1.22 $1.56 $2.87 $0.96 · $0.41
EPS (TTM) 12-point trend, +676.5% $4.67 $3.29 $2.47 $1.56 $0.92 $4.16 $0.39 $0.22 $-1.62 $-1.63 $-1.05 $-0.81
성장률 9
NBIX의 연간 성장률 데이터
지표 추세 202520242023202220212020201920182017201620152014
Revenue YoY 5-point trend, +156.0% 21.4% 24.8% 26.8% 31.3% 8.4% · · · · · · ·
Revenue CAGR 3Y 3-point trend, +11.9% 24.3% 27.6% 21.7% · · · · · · · · ·
Revenue CAGR 5Y 22.3% · · · · · · · · · · ·
EPS YoY 5-point trend, +153.9% 41.9% 33.2% 58.3% 69.6% -77.9% · · · · · · ·
EPS CAGR 3Y 3-point trend, +376.6% 44.1% 52.9% -16.0% · · · · · · · · ·
EPS CAGR 5Y 2.3% · · · · · · · · · · ·
Net Income YoY 5-point trend, +151.6% 40.2% 36.7% 61.6% 72.4% -78.0% · · · · · · ·
Net Income CAGR 3Y 3-point trend, +404.1% 45.8% 56.2% -15.0% · · · · · · · · ·
Net Income CAGR 5Y 3.3% · · · · · · · · · · ·
가치 평가 (TTM) 10
NBIX의 연간 가치 평가 (TTM) 데이터
지표 추세 202520242023202220212020201920182017201620152014
Revenue TTM 12-point trend, +2860500000.00 $2.86B $2.36B $1.89B $1.49B $1.13B $1.05B $788M $451M $162M $15M $20M $0
Net Income TTM 12-point trend, +890.5% $479M $341M $250M $154M $90M $407M $37M $21M $-143M $-141M $-89M $-61M
Market Cap 11-point trend, +731.1% $14.20B $13.57B $13.00B $11.53B $8.08B $8.96B $9.92B $6.48B $6.89B $3.36B · $1.71B
P/E 12-point trend, +210.1% 30.4 41.5 53.3 76.6 92.6 23.0 275.6 324.6 -47.9 -23.7 -53.9 -27.6
P/S 10-point trend, -97.8% 5.0 5.8 6.9 7.7 7.1 8.6 12.6 14.4 42.6 224.2 · ·
P/B 11-point trend, -46.7% 4.4 5.2 5.8 6.7 5.9 8.0 15.6 13.5 18.5 10.7 · 8.2
P / Tangible Book 6-point trend, -45.2% 4.4 5.3 5.9 6.9 5.9 8.0 · · · · · ·
P / Cash Flow 11-point trend, +150.1% 18.1 22.8 33.4 34.0 31.5 39.2 65.2 64.0 -73.0 -31.7 · -36.2
P / FCF 11-point trend, +154.1% 19.0 24.4 36.0 35.7 34.7 41.2 72.2 84.7 -68.0 -30.5 · -35.0
Earnings Yield 12-point trend, +190.6% 3.3% 2.4% 1.9% 1.3% 1.1% 4.3% 0.36% 0.31% -2.1% -4.2% -1.9% -3.6%

재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년

손익계산서
2025-12-312024-12-312023-12-312022-12-312021-12-31
매출 $2.86B$2.36B$1.89B$1.49B$1.13B
영업이익률 % 21.6%24.2%13.3%16.7%9.0%
순이익 $479M$341M$250M$154M$90M
희석 EPS $4.67$3.29$2.47$1.56$0.92
대차대조표
2025-12-312024-12-312023-12-312022-12-312021-12-31
유동비율 3.43.42.52.74.0
당좌 비율 1.91.41.11.13.6
현금 흐름
2025-12-312024-12-312023-12-312022-12-312021-12-31
잉여현금흐름 $749M$557M$362M$323M$233M

최신 뉴스 이 회사 관련 최근 헤드라인

트레이딩 시그널 진입 가격 및 위험/보상 비율을 포함한 최근 매수/매도 신호

나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목

📊

중요한 지표를 선택하세요 — 위 전체 기본 재무제표의 아무 행 옆에 있는 ➕를 클릭하세요.

선택 항목이 저장되어 모든 티커에서 유지됩니다.

기관 투자자 (13F) 827개의 제출자 · $10.1B 전체 · 기준일 2026년 6월 30일

분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.

기관 활동 — Q2 2026 대 이전 분기
신규 포지션 청산 포지션 증가함 감소 순주식 변동
153 (+61 이전 분기 대비) 62 (-37 이전 분기 대비) 300 (+11 이전 분기 대비) 223 (+8 이전 분기 대비) +9.4M

Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.

기관 가치 주식 % 추적된 13F 중 유형
Dodge & Cox $941,218,594 5,584,707 9.32% 주식
VANGUARD PORTFOLIO MANAGEMENT LLC $838,307,078 4,974,083 8.30% 주식
VANGUARD CAPITAL MANAGEMENT LLC $766,048,708 4,545,339 7.59% 주식
STATE STREET CORP $739,126,759 4,385,598 7.32% 주식
RENAISSANCE TECHNOLOGIES LLC $393,680,402 2,335,897 3.90% 주식
TWO SIGMA INVESTMENTS, LP $349,922,479 2,076,260 3.47% 주식
Vestal Point Capital, LP $316,845,800 1,880,000 3.14% 주식
GEODE CAPITAL MANAGEMENT, LLC $294,151,210 1,750,392 2.91% 주식
RTW INVESTMENTS, LP $213,689,740 1,267,925 2.12% 주식
NORGES BANK $164,132,866 973,880 1.63% 주식
FIRST TRUST ADVISORS LP $155,578,851 923,125 1.54% 주식
JACOBS LEVY EQUITY MANAGEMENT, INC $122,375,286 726,112 1.21% 주식
TWO SIGMA ADVISERS, LP $119,504,823 842,592 1.18% 주식
Swedbank AB $109,730,107 651,082 1.09% 주식
VANGUARD FIDUCIARY TRUST CO $109,170,737 647,763 1.08% 주식
DIMENSIONAL FUND ADVISORS LP $109,070,816 647,171 1.08% 주식
VICTORY CAPITAL MANAGEMENT INC $104,238,729 618,499 1.03% 주식
Caisse de depot et placement du Quebec $91,002,327 539,961 0.90% 주식
ARMISTICE CAPITAL, LLC $90,307,457 535,838 0.89% 주식
PRIMECAP MANAGEMENT CO/CA/ $82,807,988 491,340 0.82% 주식
AMERIPRISE FINANCIAL INC $79,666,260 472,708 0.79% 주식
Hood River Capital Management LLC $79,082,184 469,233 0.78% 주식
ROYAL BANK OF CANADA $73,348,000 435,207 0.73% 주식
Pictet Asset Management Holding SA $72,751,030 430,635 0.72% 주식
Gotham Asset Management, LLC $62,622,213 371,568 0.62% 주식
Fiera Capital Corp $61,558,083 365,254 0.61% 주식
BlackRock, Inc. $61,129,161 362,709 0.61% 주식
ALLIANCEBERNSTEIN L.P. $60,767,710 461,270 0.60% 주식
Vinva Investment Management Ltd $58,838,530 346,109 0.58% 주식
AustralianSuper Pty Ltd $58,817,535 348,993 0.58% 주식
GOLDMAN SACHS GROUP INC $58,206,259 345,366 0.58% 주식
BRAIDWELL LP $56,656,579 336,171 0.56% 주식
RHUMBLINE ADVISERS $52,723,054 312,832 0.52% 주식
Clearbridge Investments, LLC $47,391,031 281,194 0.47% 주식
SEIZERT CAPITAL PARTNERS, LLC $46,740,991 277,337 0.46% 주식
Swiss National Bank $45,319,062 268,900 0.45% 주식
BARCLAYS PLC $44,228,304 262,428 0.44% 주식
ENVESTNET ASSET MANAGEMENT INC $44,187,600 262,192 0.44% 주식
WORLDQUANT MILLENNIUM ADVISORS LLC $44,038,027 261,299 0.44% 주식
Candriam S.C.A. $43,932,854 260,926 0.44% 주식
BNP PARIBAS FINANCIAL MARKETS $43,921,064 260,605 0.43% 주식
FMR LLC $40,551,501 240,612 0.40% 주식
PRINCIPAL FINANCIAL GROUP INC $40,285,595 239,034 0.40% 주식
California Public Employees Retirement System $39,090,345 231,942 0.39% 주식
RENAISSANCE GROUP LLC $38,589,515 228,970 0.38% 주식
Assenagon Asset Management S.A. $37,516,902 222,606 0.37% 주식
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. $37,508,000 222,554 0.37% 주식
Sumitomo Mitsui Trust Group, Inc. $36,317,270 215,488 0.36% 주식
Carmignac Gestion $36,083,344 214,100 0.36% 주식
PFM Health Sciences, LP $35,966,549 213,407 0.36% 주식
Bridgewater Associates, LP $34,663,773 205,677 0.34% 주식
LOS ANGELES CAPITAL MANAGEMENT LLC $34,304,966 203,548 0.34% 주식
Nantahala Capital Management, LLC $33,707,000 200,000 0.33% 콜 옵션
BANK OF AMERICA CORP /DE/ $32,143,164 190,721 0.32% 주식
MORGAN STANLEY $32,058,612 190,219 0.32% 주식
SUSQUEHANNA INTERNATIONAL GROUP, LLP $31,213,608 185,200 0.31% 풋 옵션
FULLER & THALER ASSET MANAGEMENT, INC. $30,192,001 179,149 0.30% 주식
PRUDENTIAL FINANCIAL INC $29,909,064 177,465 0.30% 주식
SEB Asset Management AB $29,789,208 176,754 0.30% 주식
Ensign Peak Advisors, Inc $29,653,059 175,946 0.29% 주식
IEQ CAPITAL, LLC $29,628,432 175,800 0.29% 주식
MACKENZIE FINANCIAL CORP $29,609,071 175,685 0.29% 주식
NEW YORK STATE COMMON RETIREMENT FUND $29,573,511 175,474 0.29% 주식
Korea Investment CORP $29,154,701 172,989 0.29% 주식
PKO BP BANKOWY Universal Pension Society JSC $28,786,115 170,802 0.29% 주식
Zurich Insurance Group Ltd/FI $28,618,254 169,806 0.28% 주식
Impax Asset Management Group plc $26,965,600 160,000 0.27% 주식
Nearwater Capital Markets, Ltd $26,122,925 155,000 0.26% 주식
Mariner, LLC $25,627,342 152,055 0.25% 주식
Integral Health Asset Management, LLC $25,281,000 150,000 0.25% 주식
Rock Springs Capital Management LP $24,395,441 144,750 0.24% 주식
Zurcher Kantonalbank (Zurich Cantonalbank) $23,738,829 140,854 0.24% 주식
Fisher Asset Management, LLC $22,769,751 135,104 0.23% 주식
Aware Super Pty Ltd as trustee of Aware Super $22,056,175 130,870 0.22% 주식
RAYMOND JAMES FINANCIAL INC $22,009,323 130,592 0.22% 주식
Hudson Bay Capital Management LP $21,909,550 130,000 0.22% 주식
Life Cycle Investment Partners Ltd $21,287,319 126,308 0.21% 주식
VIRGINIA RETIREMENT SYSTEMS ET Al $20,937,370 147,623 0.21% 주식
DNB Asset Management AS $20,280,996 120,337 0.20% 주식
JANE STREET GROUP, LLC $20,072,518 119,100 0.20% 풋 옵션
Sarissa Capital Management LP $19,639,889 116,533 0.19% 주식
Andra AP-fonden $19,522,682 148,191 0.19% 주식
AMERICAN CENTURY COMPANIES INC $19,061,140 113,099 0.19% 주식
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main $18,885,863 112,059 0.19% 주식
Man Group plc $18,859,404 111,902 0.19% 주식
Mitsubishi UFJ Asset Management Co., Ltd. $18,788,956 111,484 0.19% 주식
UBS Group AG $18,243,577 108,248 0.18% 주식
Robeco Institutional Asset Management B.V. $18,197,736 107,976 0.18% 주식
LOOMIS SAYLES & CO L P $18,108,412 107,446 0.18% 주식
Retirement Systems of Alabama $17,527,134 103,997 0.17% 주식
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM $17,474,389 132,643 0.17% 주식
ING GROEP NV $17,224,277 102,200 0.17% 주식
Legal & General Group Plc $17,176,748 101,918 0.17% 주식
RICE HALL JAMES & ASSOCIATES, LLC $16,886,364 100,195 0.17% 주식
Universal- Beteiligungs- und Servicegesellschaft mbH $16,827,572 99,912 0.17% 주식
CWM, LLC $16,696,728 126,740 0.17% 주식
CAPITAL FUND MANAGEMENT S.A. $16,536,148 98,117 0.16% 주식
Clark Capital Management Group, Inc. $15,629,612 92,738 0.15% 주식
Distillate Capital Partners LLC $15,604,993 92,592 0.15% 주식
LAZARD ASSET MANAGEMENT LLC $15,399,211 91,371 0.15% 주식

회사 내부자 42 명의 내부자 · 21 임원 · 15 이사

내부자 역할 마지막 활동 보유 주식 수 매수 12개월 매도 12개월 순매수/매도 12개월
Kyle Gano Chief Executive Officer 2025년 2월 13일 M 139,907 0 0 $0
Matt Abernethy Chief Financial Officer 2025년 2월 13일 M 35,810 0 0 $0
Timothy Coughlin Chief Financial Officer 2017년 2월 6일 S 137,961 0 0 $0
David-Alexandre C Gros President & COO 2017년 2월 6일 A — 0 0 $0
Ingrid Delaet Chief Regulatory Officer 2026년 7월 10일 M 16,225 0 5 $-3,747,962
Darin Lippoldt Chief Legal Officer 2026년 7월 9일 M 54,729 0 4 $-3,497,443
Sanjay Chandru Keswani Chief Medical Officer 2026년 6월 2일 F 1,479 0 0 $0
Julie Cooke Chief Human Resources Officer 2026년 6월 2일 M 22,374 0 1 $-2,200,685
David W. Boyer Chief Corp. Affairs Officer 2025년 2월 13일 M 3,565 0 0 $0
Eiry Roberts Chief Medical Officer 2025년 2월 13일 M 35,640 0 0 $0
Eric Benevich Chief Commercial Officer 2025년 2월 13일 M 44,689 0 0 $0
Malcolm Lloyd-Smith Chief Integration Officer 2023년 2월 8일 S 42,337 0 0 $0
Dimitri E. Grigoriadis Chief Research Officer 2022년 1월 31일 A 82,273 0 0 $0
Haig P. Bozigian Chief Development Officer 2021년 2월 8일 A 157,651 0 0 $0
Christopher Flint Obrien Former Chief Medical Officer 2018년 2월 5일 A 55,946 0 0 $0
VALEUR JENSEN MARGARET E EVP and General Counsel 2011년 8월 31일 A 118,256 0 0 $0
Richard J Ranieri Sr. VP, Human Resources 2008년 2월 27일 A 9,667 0 0 $0
Wendall Wierenga EVP, Research & Development 2006년 1월 19일 A 5,023 0 0 $0
Henry Pan Executive VP and CMO 2005년 6월 3일 A 11,216 0 0 $0
Robert J Little SVP, Commercial Operations 2005년 2월 18일 A — 0 0 $0
SAUNDERS JOHN Vice President Research (Chem) 2003년 12월 18일 S 7,966 0 0 $0
Leslie V Norwalk 이사 2026년 7월 29일 M 2,430 0 2 $-437,584
SHERWIN STEPHEN A 이사 2026년 6월 5일 M 15,860 0 5 $-4,132,990
William H Rastetter 이사 2026년 5월 27일 A 43,678 0 1 $-2,732,760
Kevin Charles Gorman 이사 2026년 5월 27일 A 511,293 0 1 $-37,824,431
Christine A Poon 이사 2026년 5월 27일 A 4,753 0 0 $0
POPS RICHARD F 이사 2026년 5월 27일 A 37,798 0 1 $-2,364,750
LYONS GARY A 이사 2026년 5월 27일 A 122,141 0 1 $-2,289,150
MORROW GEORGE J 이사 2026년 5월 27일 A 10,386 0 1 $-2,150,550
Johanna Mercier 이사 2025년 5월 22일 M 3,535 0 0 $0
Alfred Sandrock 이사 2019년 5월 22일 A — 0 0 $0
Corinne H Nevinny 이사 2018년 5월 24일 A 43,283 0 0 $0
Thomas W Mitchell 이사 2015년 5월 28일 A 1,000 0 0 $0
VALE WYLIE W 이사 2011년 5월 25일 A 231,372 0 0 $0
Adrian Adams 이사 2006년 6월 30일 A — 0 0 $0
NEUROCRINE BIOSCIENCES INC 10% 소유주 2023년 2월 23일 P 8,575,316 0 0 $0
Jude Onyia — 2026년 8월 4일 G 20,996 0 1 $-1,762,710
Shalini Sharp — 2026년 5월 27일 A 4,088 0 0 $0
MOLLICA JOSEPH A — 2017년 5월 22일 A 56,042 0 0 $0
HAWRAN PAUL W — 2006년 9월 18일 J 132,000 0 0 $0
Lawrence Steinman — 2005년 3월 2일 S 15,500 0 0 $0
CONLON PAUL J — 2003년 12월 16일 S 57,335 0 0 $0

SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당

행동주의자 및 5% 이상 소유자 1 보유

SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.

제출자 제출됨 지분 상태 목적 제출
Neurocrine Biosciences, Inc. ×3 제출 서류 2023년 2월 24일 — 최초 제출 — SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

ETF 보유 현황 129 ETF 보유

가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.

펀드 비중 단위 기준일 출처
IBRN · iShares Trust 3.71% 1,793 SH 2026년 8월 8일 일간
PBE · Invesco Exchange-Traded Fund Trust 2.51% 55,704 SH 2026년 8월 8일 일간
MCOW · Pacer Funds Trust 2.17% 162 NS 2026년 4월 30일 N-PORT
FGSI · First Trust Exchange-Traded Fund IV 2.01% 457 NS 2026년 4월 30일 N-PORT
POWA · Invesco Exchange-Traded Self-Indexe… 1.97% 22,094 SH 2026년 8월 8일 일간
SMRI · EA Series Trust 1.95% 79,947 NS 2026년 4월 30일 N-PORT
GRPM · Invesco Exchange-Traded Fund Trust 1.78% 55,458 SH 2026년 8월 8일 일간
XMHQ · Invesco Exchange-Traded Fund Trust 1.74% 599,955 SH 2026년 8월 8일 일간
BUL · Pacer Funds Trust 1.66% 16,032 NS 2026년 4월 30일 N-PORT
BBP · ETFis Series Trust I 1.38% 6,192 NS 2026년 4월 30일 N-PORT
ILDR · First Trust Exchange-Traded Fund VI… 1.29% 23,318 NS 2026년 5월 31일 N-PORT
IBB · iShares Trust 1.22% 725,434 SH 2026년 8월 8일 일간
RFG · Invesco Exchange-Traded Fund Trust 1.16% 25,502 SH 2026년 8월 8일 일간
AGNG · Global X Funds 1.12% 5,792 NS 2026년 5월 31일 N-PORT
IBBQ · Invesco Exchange-Traded Fund Trust … 1.12% 5,472 SH 2026년 8월 8일 일간
LABU · Direxion Shares ETF Trust 0.95% 37,476 NS 2026년 4월 30일 N-PORT
AGRW · ALLSPRING EXCHANGE-TRADED FUNDS TRU… 0.93% 7,516 NS 2026년 4월 30일 N-PORT
IVOG · VANGUARD ADMIRAL FUNDS 0.89% 99,214 SH 2026년 8월 8일 일간
FXH · First Trust Exchange-Traded AlphaDE… 0.87% 57,454 NS 2026년 4월 30일 N-PORT
IJK · iShares Trust 0.86% 588,275 SH 2026년 8월 8일 일간
COWG · Pacer Funds Trust 0.81% 132,963 NS 2026년 4월 30일 N-PORT
BIB · ProShares Trust 0.80% 3,712 NS 2026년 5월 31일 N-PORT
QQQJ · Invesco Exchange-Traded Fund Trust … 0.79% 57,321 SH 2026년 8월 8일 일간
TMFX · RBB Fund, Inc. 0.76% 1,542 NS 2026년 5월 31일 N-PORT
ABOT · Abacus FCF ETF Trust 0.72% 240 NS 2026년 4월 30일 N-PORT
CLSE · Trust for Professional Managers 0.66% 25,529 NS 2026년 5월 31일 N-PORT
MIDE · DBX ETF Trust 0.64% 136 NS 2026년 5월 29일 N-PORT
JDOC · J.P. Morgan Exchange-Traded Fund Tr… 0.63% 533 NS 2026년 4월 30일 N-PORT
IQSM · New York Life Investments ETF Trust 0.55% 13,166 NS 2026년 4월 30일 N-PORT
SMDX · Tidal Trust III 0.55% 5,215 NS 2026년 4월 30일 N-PORT
XJH · iShares Trust 0.51% 13,589 SH 2026년 8월 8일 일간
ISCG · iShares Trust 0.50% 31,557 SH 2026년 8월 8일 일간
QVMM · Invesco Exchange-Traded Fund Trust … 0.49% 13,131 SH 2026년 8월 8일 일간
VBK · VANGUARD INDEX FUNDS 0.46% 1,331,820 SH 2026년 8월 8일 일간
IVOO · VANGUARD ADMIRAL FUNDS 0.46% 162,408 SH 2026년 8월 8일 일간
QLV · FlexShares Trust 0.46% 5,915 NS 2026년 4월 30일 N-PORT
IJH · iShares Trust 0.44% 3,469,295 SH 2026년 8월 8일 일간
SDG · iShares Trust 0.42% 4,563 SH 2026년 8월 8일 일간
FNY · First Trust Exchange-Traded AlphaDE… 0.40% 15,614 NS 2026년 4월 30일 N-PORT
IWP · iShares Trust 0.39% 493,090 SH 2026년 8월 8일 일간
PTMC · Pacer Funds Trust 0.39% 11,519 NS 2026년 4월 30일 N-PORT
USMV · iShares Trust 0.35% 534,448 SH 2026년 8월 8일 일간
MVV · ProShares Trust 0.34% 3,468 NS 2026년 5월 31일 N-PORT
SXQG · EXCHANGE TRADED CONCEPTS TRUST 0.34% 1,461 NS 2026년 5월 31일 N-PORT
BKMC · BNY Mellon ETF Trust 0.34% 16,076 NS 2026년 4월 30일 N-PORT
SCHM · SCHWAB STRATEGIC TRUST 0.29% 271,303 NS 2026년 5월 31일 N-PORT
MIDU · Direxion Shares ETF Trust 0.26% 1,662 NS 2026년 4월 30일 N-PORT
BBMC · J.P. Morgan Exchange-Traded Fund Tr… 0.26% 40,014 NS 2026년 4월 30일 N-PORT
IYH · iShares Trust 0.26% 59,243 SH 2026년 8월 8일 일간
ISCB · iShares Trust 0.25% 4,488 SH 2026년 8월 8일 일간